-
“Standing together against injustice” – a message from Per Falk, President and Chief Science Officer at Ferring
in Uncategorized on“Standing together against injustice” – a message from Per Falk, President and…
0 -
Ferring Statement on the COVID-19 (novel coronavirus disease) Pandemic and Reproductive Medicine
in Uncategorized onThe health and safety of our patients, our employees and their families are Ferring’s number one priority. As the situation regarding COVID-19 (novel coronavirus disease) is evolving rapidly, Ferring is committed to following appropriate global, regional and local medical authority guidance to prevent infection spread and to keep patients, our employees and their families safe.
-
Swissmedic approves Carbetocin Ferring for the prevention of postpartum haemorrhage in all births
in Uncategorized onFerring Pharmaceuticals today welcomes the Swissmedic approval of Carbetocin Ferring, a heat-stable formulation of carbetocin, for the prevention of excessive bleeding after childbirth following all births, both vaginal and caesarean section. Every year, 14 million women experience excessive bleeding after birth, also known as postpartum haemorrhage…
-
Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660
in Uncategorized onToday, Rebiotix and Ferring Pharmaceuticals announced positive preliminary findings from their ongoing pivotal Phase 3 trial of the investigational microbiome-based treatment, RBX2660. These preliminary positive efficacy findings mark an important milestone, advancing RBX2660 in its clinical…
-
Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
in Uncategorized onRebiotix, a Ferring company, announced today that it has completed enrollment of the pivotal Phase 3 clinical trial for RBX2660, an investigational therapy…
-
Ferring’s Propess® is the first pharmacological treatment for cervical ripening to be approved in Japan for over 20 years
in Uncategorized onFerring Pharmaceuticals today announced that Propess® (dinoprostone) has been approved by the Minister of Health, Labour and Welfare (MHLW)…
-
FerGene Appoints David Meek Chief Executive Officer
in Uncategorized onFerGene, a new gene therapy company launched by Ferring Pharmaceuticals and Blackstone Life Sciences in November, today announced the appointment of David Meek as President and Chief Executive Officer …
-
FerGene announces pivotal Phase 3 study of nadofaragene firadenovec
in Uncategorized onFerGene, a new gene therapy company formed by Ferring Pharmaceuticals and Blackstone Life Sciences, announced today positive results from the pivotal Phase 3 clinical trial evaluating nadofaragene firadenovec …
-
Ferring and Blackstone Life Sciences invest over $570 million USD in novel gene therapy for bladder cancer patients
in Uncategorized onFerring and Blackstone Life Sciences invest over $570 million USD in novel…
-
Heat-stable carbetocin has been added to the WHO Essential Medicines List for the prevention of excessive bleeding after childbirth
in Uncategorized onFerring Pharmaceuticalstoday welcomes the World Health Organization’s (WHO) addition of heat-stable carbetocin to the WHO Model List of Essential Medicines (EML)…
Uncategorized
Uncategorized